GSK Scraps Chronic Cough Drug After Mixed Trial Results
2026-07-17 11:08:04
GSK Plc halted development of its experimental chronic cough drug after mixed trial results, saying the treatment was unlikely to transform patient care, according to Bloomberg.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
Xiaomi Group to Hold Board Meeting on August 18, 2026Next article：
前日本部长指印度拖慢高铁项目
